Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones
Sutro Biopharma (STRO) reported a strong performance for 2021, with revenue increasing to $61.9 million from $42.7 million in 2020, driven by collaborations with Merck, BMS, and EMD Serono. The company is advancing its lead candidate, STRO-002, which targets ovarian cancer, completing its Phase 1 trial enrollment and planning a registrational path forward. However, operating expenses rose to $160.4 million, up from $113.8 million, partly due to stock-based compensation. Sutro's cash reserves stood at $229.5 million, providing runway into late 2023.
- Revenue for 2021 increased to $61.9 million, up from $42.7 million in 2020.
- Completed enrollment of STRO-002 Phase 1 trial for ovarian cancer.
- Plans for registrational study for STRO-002 in mid-2022.
- Operating expenses rose to $160.4 million in 2021 from $113.8 million in 2020.
- Uncertain initial payment of $40 million from Tasly Biopharmaceuticals regarding STRO-002.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer therapeutics, today reported its financial results for the full year 2021, its recent business highlights, and a preview of anticipated select milestones in 2022.
"We are proud of the achievements at Sutro, as our proprietary cell-free platform has enabled five clinical-stage product candidates, including our internal programs, STRO-002 and STRO-001, and our collaborator programs, CC-99712, M1231, and VAX-24," said Bill Newell, Sutro's Chief Executive Officer. "We've made significant strides in the development of STRO-002 for ovarian cancer by completing the enrollment of the Phase 1 trial late last year. We intend to work with regulatory agencies on a registrational path forward for patients with ovarian cancer, utilizing our Fast Track Designation. Additionally, we are exploring the therapeutic benefit of STRO-002 in other tumor types. We are currently enrolling patients in an endometrial cohort and plan to initiate a NSCLC study later this year. We continue to explore all strategies to accelerate the development of STRO-002 to provide a potential new therapy for patients suffering from advanced cancers with limited durable treatment options."
Recent Business Highlights and Anticipated 2022 Select Milestones
STRO-002, FolRα-Targeting Antibody-Drug Conjugate (ADC): STRO-002 is being studied in the clinic, in both the United States and Europe, for patients with ovarian cancer and endometrial cancer.
- The Phase 1 dose-expansion cohort for patients with advanced ovarian cancer was initiated in January 2021 and enrollment was completed in November 2021.
- Sutro reported initial data for the dose-expansion cohort in January 2022 at a Company KOL Virtual Event, providing data on efficacy and safety, and initial insights on a potential go-forward dosing regimen and biomarker enrichment strategy.
- Additional data on efficacy, safety, and durability from the dose-expansion cohort are expected to be reported in the second half of 2022.
- Regulatory discussions on a potential registrational study for patients with advanced ovarian cancer are planned for around mid-year 2022.
- Sutro is enrolling patients in a combination study of STRO-002 with bevacizumab for patients with advanced ovarian cancer and a dose-expansion study of STRO-002 for patients with endometrial cancer.
STRO-001, CD74-Targeting ADC: The Phase 1 study for patients with B‑cell malignancies, including patients with non-Hodgkin's lymphoma and multiple myeloma, continues in dose escalation.
- Dose escalation is ongoing to achieve a recommended phase 2 dose (RP2D), with the last reported doses of 5.0 mg/kg in the multiple myeloma (MM) cohort and 5.0 mg/kg in the non-Hodgkin's lymphoma (NHL) cohort.
Additional Pipeline Programs: Research and preclinical development are underway for several internal candidates.
- Sutro announced multiple discovery and preclinical candidates, including ADCs targeting ROR1 and Tissue Factor, a 5T4-CD3 bispecific T-Cell Engager (TCE), and cytokine derivatives, including IFNα, IL-12, and IL-18.
- Discovery and preclinical work on these programs are underway to determine Sutro's next programs to advance to the clinic.
Collaboration Updates: Sutro continues to seek to maximize the value of its proprietary cell-free platform by working with partners on programs in multiple disease spaces and geographies and has received from collaborators an aggregate of approximately
- Sutro is manufacturing initial drug supply for the potential clinical development of the Merck cytokine derivative program, which is focused on two distinct cytokine derivative molecules for the treatment of cancer.
- Sutro continues to manufacture clinical trial materials for Bristol Myers Squibb's (BMS) CC-99712, a BCMA‑targeting ADC, for treatment of multiple myeloma, as BMS continues its Phase 1 clinical trial, which has been expanded to include a study in combination with a gamma secretase inhibitor.
- Sutro will supply cell-free extract to Vaxcyte for the clinical supply of VAX-24, which is designed to prevent invasive pneumococcal disease. Vaxcyte announced in February 2022 that the first participants were dosed in the Phase 1/2 clinical study of VAX-24.
- Sutro plans to support BioNova Pharmaceuticals (BioNova) in clinical trial initiations for STRO-001 in the Greater China market and provide clinical drug supply as needed.
- Under the licensing agreement with Tasly Biopharmaceuticals (Tasly) to develop and commercialize STRO-002 in Greater China, Tasly is obligated to make an initial payment of
$40 million to Sutro. In February 2022, Tasly indicated to Sutro that it would like to discuss and renegotiate the terms of the agreement. Based on the currently ongoing discussions, Sutro believes that substantial uncertainty exists as to whether Tasly will timely deliver the initial payment to Sutro, despite Sutro having performed its related obligations upon execution of the agreement. Accordingly, Sutro is considering all remedies available. Of note, no new or updated clinical data have been shared by Sutro with Tasly subsequent to the STRO-002 initial dose-expansion data release by Sutro in January 2022.
Full Year 2021 Financial Highlights
Cash, Cash Equivalents and Marketable Securities
As of December 31, 2021, Sutro had cash, cash equivalents and marketable securities of
Unrealized Loss from Decrease in Value of Vaxcyte Common Stock
As of December 31, 2021, Sutro held approximately 1.6 million shares of Vaxcyte common stock, with a fair value of
Revenue
Revenue was
Operating Expenses
Total operating expenses for the year ended December 31, 2021 were
About Sutro Biopharma
Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
Sutro's proprietary and integrated cell-free protein synthesis platform XpressCF® and site-specific conjugation platform XpressCF+™ led to the discovery of STRO-001 and STRO-002, Sutro's first two internally-developed ADCs. STRO-001 is a CD74-targeting ADC currently under investigation in a Phase 1 clinical trial for patients with advanced B-cell malignancies and was granted Orphan Drug Designation by the FDA for multiple myeloma. STRO-002, a folate receptor alpha (FolRα)-targeting ADC, is currently being investigated in a Phase 1 clinical trial for patients with ovarian and endometrial cancers and was granted Fast Track designation by the FDA for ovarian cancer. A third product candidate, CC-99712, a BCMA-targeting ADC, which is part of Sutro's collaboration with Bristol Myers Squibb, formerly Celgene Corporation, is enrolling patients for its Phase 1 clinical trial of patients with multiple myeloma and has received Orphan Drug Designation from the FDA. A fourth product candidate, M1231, a MUC1-EGFR, bispecific ADC, which is part of Sutro's collaboration with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), is enrolling patients for its Phase 1 clinical trial of patients with metastatic solid tumors, non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma. These four product candidates resulted from Sutro's XpressCF® and XpressCF+™ technology platforms. Bristol Myers Squibb and EMD Serono have worldwide development and commercialization rights for CC-99712 and M1231, respectively, for which Sutro is entitled to milestone or contingent payments and tiered royalties.
Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need. To date, Sutro's platform has led to ADCs, bispecific antibodies, cytokine-based immuno-oncology therapies, and vaccines directed at precedented targets in clinical indications where the current standard of care is suboptimal.
Sutro's platform allows it to accelerate discovery and development of potential first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates. In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotechnology companies to discover and develop novel, next-generation therapeutics.
Follow Sutro on Twitter, @Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities, timing of announcements of clinical results, potential benefits of STRO-002 and the Company's other product candidates and platform, potential future milestone and royalty payments, and potential market opportunities for STRO-002 and the Company's other product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates and the Company's ability to successfully leverage Fast Track designation, the market size for the Company's product candidates to be smaller than anticipated, the impact of the COVID-19 pandemic on the Company's business, clinical trial sites, supply chain and manufacturing facilities, the Company's ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company's ability to fund development activities and achieve development goals, the Company's ability to protect intellectual property, the value of the Company's holdings of Vaxcyte common stock, and the Company's commercial collaborations with third parties and other risks and uncertainties described under the heading "Risk Factors" in documents the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Investor Contact
Annie J. Chang
Sutro Biopharma
(650) 801-5728
ajchang@sutrobio.com
Media Contact
Maggie Beller
Russo Partners
(646) 942-5631
Maggie.beller@russopartnersllc.com
Sutro Biopharma, Inc. Selected Statements of Operations Financial Data (Unaudited) (In thousands, except per share amounts) | ||||||||||||
Year Ended December 31, | ||||||||||||
2021 | 2020 | 2019 | ||||||||||
Revenue | 61,880 | 42,722 | 42,736 | |||||||||
Operating expenses | ||||||||||||
Research and development | 104,400 | 76,961 | 65,612 | |||||||||
General and administrative | 56,004 | 36,818 | 32,592 | |||||||||
Total operating expenses | 160,404 | 113,779 | 98,204 | |||||||||
Loss from operations | (98,524) | (71,057) | (55,468) | |||||||||
Interest income | 577 | 1,508 | 4,074 | |||||||||
Unrealized (loss) gain on equity securities | (4,454) | 41,498 | — | |||||||||
Interest and other expense, net | (3,137) | (4,077) | (4,350) | |||||||||
Net loss | $ | (105,538) | $ | (32,128) | $ | (55,744) | ||||||
Net loss per share, basic and diluted | $ | (2.29) | $ | (0.99) | $ | (2.43) | ||||||
Weighted-average shares used in computing basic and diluted net loss per share | 46,119,089 | 32,573,469 | 22,958,577 | |||||||||
Sutro Biopharma, Inc. Selected Balance Sheet Financial Data (Unaudited) (In thousands) | ||||||||
December 31, | ||||||||
2021 | 2020 | |||||||
(1) | (2) | |||||||
Assets | ||||||||
Cash, cash equivalents and marketable securities | $ | 229,532 | $ | 326,493 | ||||
Accounts receivable | 12,454 | 5,559 | ||||||
Investment in equity securities | 37,181 | 41,644 | ||||||
Property and equipment, net | 22,550 | 12,935 | ||||||
Operating lease right-of-use assets | 29,041 | – | ||||||
Other assets | 10,650 | 7,480 | ||||||
Total assets | $ | 341,408 | $ | 394,111 | ||||
Liabilities and Stockholders' Equity | ||||||||
Accounts payable and other liabilities | $ | 25,974 | $ | 16,815 | ||||
Deferred revenue | 5,496 | 20,703 | ||||||
Operating lease liability | 32,261 | – | ||||||
Debt | 25,113 | 24,545 | ||||||
Total liabilities | 88,844 | 62,063 | ||||||
Total stockholders' equity | 252,564 | 332,048 | ||||||
Total Liabilities and Stockholders' Equity | $ | 341,408 | $ | 394,111 | ||||
(1) | The condensed balance sheet as of December 31, 2021 was derived from the audited financial |
(2) | The condensed balance sheet as of December 31, 2020 was derived from the audited financial |
View original content:https://www.prnewswire.com/news-releases/sutro-biopharma-reports-full-year-2021-financial-results-business-highlights-and-anticipated-2022-milestones-301491587.html
SOURCE Sutro Biopharma
FAQ
What were Sutro Biopharma's revenue figures for 2021?
What is the status of STRO-002's clinical trials?
What are Sutro Biopharma's operating expenses for 2021?
Is there any uncertainty regarding Sutro's collaboration agreements?
